TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00683020

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATSM Intervention
Description: The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients.
Study: NCT00494975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band UVB phototherapy , long wave UVA phototherapy
Description: A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Narrow band UVB phototherapy , long wave UVA phototherapy
Description: A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
Study: NCT03703713

Intervention type: DRUG
Intervention: Sodium chloride
Description: Treatment with Sodium chloride
Study: NCT02841709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules
Study: NCT03594123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2 or 3 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 0.5 to 3 mg tablet
Study: NCT04238767

Intervention type: DRUG
Intervention: Dolutegravir
Description: Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
Study: NCT02192099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel (225 mg/450 mg IV administration)
Description: Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
Study: NCT02057848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low amount of carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high amount of carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid-acting carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
Study: NCT01124851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: See arm description for details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: See arm description for details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: See arm description for details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm description for details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm description for details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm description for details
Study: NCT03827109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group educational activities
Description: Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group educational activities
Description: Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBD educational website
Description: Website with age-appropriate educational information, including information from the group educational activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBD educational website
Description: Website with age-appropriate educational information, including information from the group educational activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly check-in calls from program coordinator
Description: Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly check-in calls from program coordinator
Description: Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun group activities
Description: Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent support group
Description: Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
Study: NCT03309956

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Monitor
Description: A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Zio Patch
Description: The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
Study: NCT03167671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy
Description: AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Up to 20 sessions of traditional physical therapy
Study: NCT03579771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT03917771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early lymphedema detection
Description: Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual follow-up
Description: Usual follow-up carried out in GO consultation
Study: NCT01900236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on behavioral motivational interviewing (MI) technique
Description: In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
Study: NCT04025879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study: NCT01166568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PresVIEW Scleral Implants
Description: Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PresVIEW Scleral Implants
Description: Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
Study: NCT03763500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based education
Description: A six-step Internet-based patient education.
Study: NCT02313103

Intervention type: DRUG
Group type: OTHER
Intervention: lofexidine HCl
Description: 400 micrograms

Intervention type: DRUG
Group type: OTHER
Intervention: lofexidine HCl
Description: 400 micrograms
Study: NCT03457909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS-MCE
Description: During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
Study: NCT03868709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine inhalation
Description: Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study: NCT00215319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar I/F with cage and pedicle screws
Description: Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
Study: NCT03679741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL Lens
Description: Acuvue OASYS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL Lens
Description: Acuvue OASYS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST Lens
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST Lens
Description: senofilcon A
Study: NCT02606500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elonva
Description: 20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonva
Description: 20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years.
Study: NCT01501942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Description: AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffered Saline
Description: The matching placebo is an oral solution of phosphate buffered saline
Study: NCT04192500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent seasonal influenza vaccine (Influvac TetraTM)
Description: One single administration intramuscularly at Day 1.
Study: NCT00565305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: 4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: 4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
Study: NCT02846948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused assessed echocardiography
Description: Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
Study: NCT00861809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 25 mg
Description: 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 25 mg
Description: 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 25 mg
Description: 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 50 mg
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 50 mg
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 50 mg
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 1250 mg
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 1250 mg
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 1250 mg
Description: 125 mg
Study: NCT04659538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPTIS Embolic Protection device
Description: The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
Study: NCT02403700

Intervention type: DEVICE
Intervention: Cone beam computed tomography (CBCT)
Description: Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
Study: NCT03186066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flamingo Device
Description: Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
Study: NCT00622609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK249320A
Description: GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride intravenous infusion will be given as matching placebo.
Study: NCT01310296

Intervention type: DRUG
Group type: OTHER
Intervention: Lofexidine hydrochloride
Description: Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride
Description: Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min